ArticleCancers2025
Assessing Ultrasound as a Tool for Monitoring Tumor Regression During Chemotherapy: Insights from a Cohort of Breast Cancer Patients.
Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Ultrasound for predicting pathological response to neoadjuvant chemotherapy in patients with breast cancer: a systematic review and meta-analysis.BMC cancer · 2026Pooled it
- Nutritional Impact on Breast Cancer in Menopausal and Post-Menopausal Patients Treated with Aromatase Inhibitors.Cancers · 2025Review
- Monitoring Pharmacological Treatment of Breast Cancer with MRI.Current issues in molecular biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesAccurate assessment of tumor response to neoadjuvant chemotherapy (NAC) in breast cancer is critical for optimizing treatment strategies. While magnetic resonance imaging (MRI) and mammography are commonly used for response evaluation, they have inherent limitations. Ultrasound (US) has emerged as a promising, cost-effective, and real-time alternative. This study aimed to evaluate the effectiveness of US in tracking tumor regression during NAC and its correlation with pathologic tumor regression grade (TRG).
methodsThis study included 282 breast cancer patients undergoing NAC. Tumor size was measured using ultrasound at three key time points: pre-chemotherapy, after four cycles, and post-chemotherapy. Spearman's correlation was used to assess the relationship between US-measured tumor changes and TRG. Multinomial logistic regression and receiver operating characteristic (ROC) curve analyses were performed to determine the predictive accuracy of the measurements from our US in identifying pathologic complete response (pCR).
conclusionsUltrasound is a reliable, real-time imaging tool for monitoring NAC response in breast cancer patients. Its ability to predict pCR and track tumor shrinkage highlights its potential for treatment adaptation. Standardization of US protocols and integration with AI-based analysis may further improve its clinical utility, making it a valuable adjunct in breast cancer treatment monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.